We Work For Health

A major milestone for American investment: Biopharma companies have now committed more than $500B to expand manufacturing capabilities and strengthen the U.S. supply chain. Explore the latest activity in our U.S. Biopharma Investment Watch: weworkforhealth.org/investinamerica

From advocacy to education, We Work For Health unites diverse stakeholders committed to driving breakthroughs and supporting the delivery of life‑enhancing treatments. Visit the website to learn more: weworkforhealth.org/about

China is tailgating America on the biopharma highway. WWFH Executive Director @DLeonard_DC with a warning to policymakers: "Objects in rearview mirror are larger than they appear." weworkforhealth.org/post/europe-s-…

Policies intended to accelerate access can undermine innovation if they weaken the intellectual property systems that sustain drug development in the first place. Henry Hadad of @bmsnews examines how recent EU IP reforms could reshape investment decisions and ultimately limit patient access to future therapies: weworkforhealth.org/post/protectin…

Most favored nation doesn't just import European drug prices, @Graham_Cookson told U.S. policymakers. "It imports our philosophy, which is very different." weworkforhealth.org/post/europe-s-…

Europeans have grown somewhat resigned to certain drugs being unavailable, @KMAndersonDC said at a recent Hill event. "People would riot in the streets if we couldn't access it here in America." weworkforhealth.org/post/europe-s-…

New Jersey is home to one of the world's leading life sciences hubs – supporting hundreds of thousands of jobs and fueling billions in economic activity. MFN pricing puts this all at risk and would limit patient access to medicines, reduce R&D investment, and slow the next generation of cures. More from WWFH’s @DLeonard_DC and @ChrissyButeas of @HINJ_ORG: weworkforhealth.org/post/most-favo…

Dr. Lou Garrison of @UW_Pharmacy on downstream effect of government-imposed price controls: "If they have less sales, we're all going to get less R&D. We're all going to get less health benefits from these global public goods." weworkforhealth.org/post/europe-s-…

Patients in rural communities already struggle with limited access and barriers to care. MFN proposals could compound those challenges. More from former Ohio State Rep. Margaret Ann Ruhl of @NationalGrange: yourohionews.com/knox-county/mf…

Biopharma companies aren't just announcing plans to invest more in America. They're doing it. Here's a look at where concrete has been poured, boosting U.S. jobs and access to treatment. weworkforhealth.org/post/promises-…

Patients in rural communities already struggle with limited access and barriers to care. MFN proposals could compound those challenges. More from former Ohio State Rep. Margaret Ann Ruhl of @NationalGrange: yourohionews.com/knox-county/mf…

Behind every new medicine is a long journey marked by risk and enormous investment. Strong IP protections give innovators the confidence to take that journey and investors the certainty to support it. On #WorldIPDay, we recognize how IP helps turn scientific possibility into treatments and cures for patients.

The United States leads the world in life sciences by protecting innovation. Strong intellectual property policy makes it possible for groundbreaking ideas to scale, compete globally, and become real treatments for patients. This #WorldIPDay is a reminder that America’s edge in biopharma depends on keeping IP strong at home.

The U.S. cannot lead in innovation without strong intellectual property protections. While Washington stalls, China is advancing. WWFH Executive Director @DLeonard_DC explains why this moment demands action, not delay: linkedin.com/pulse/caution-…

We Work For Health proudly presents the Healthcare Innovation Leadership Award to @RepFitzgerald and @RepKnott for their leadership in protecting the intellectual property system that drives biomedical breakthroughs and patient access: weworkforhealth.org/post/wwfh-pres…

Lower prices mean little if patients lose access to care. MFN pricing could restrict innovation and reduce treatment options. Listen to experts break down the real‑world consequences for patients: weworkforhealth.org/post/from-poli…

From lifesaving medicines to cutting‑edge medical technologies, progress depends on policies that support discovery and scale. A look at how intellectual property has powered U.S. innovation for 250 years, and why it remains critical to future breakthroughs: weworkforhealth.org/post/250-years…

Endpoints Signal head Tom Randall (@tsrandall) found a "pretty startling" sentiment among biopharma industry leaders. Washington should weigh it carefully before importing European drug prices. weworkforhealth.org/post/europe-s-…

In a new video, WWFH Executive Director @DLeonard_DC shares why intellectual property remains central to innovation and U.S. leadership in health care ahead of World Intellectual Property Day on April 26: weworkforhealth.org/post/world-ip-…